Below are our currently enrolling studies for patients with rheumatoid arthritis.
Sponsor: Crescendo Bioscience
Protocol Number: 133-CL-01
In this 12-month multi-center prospective, site-randomized, two-arm trial, approximately 318 biologic-naïve subjects with RA who are candidates for treatment intensification due to inadequate response to MTX monotherapy will be enrolled at up to 60 study sites.
Detailed Information:
To learn more or see if you qualify: Click Here
Sponsor: Aqtual, Inc.
Protocol Number: PRIMA – 102
The primary goal of this study is to assess a cfDNA-based blood test using genetic, transcriptomic and/or epigenetic information to help doctors predict the best treatment options for rheumatoid arthritis (RA) patients with inadequate response or intolerance to previous therapies.
Detailed Information:
To learn more or see if you qualify: Click Here
